Similarly, an analysis of a diffuse large B-cell lymphoma patient cohort receiving standard treatment in the TCGA database showed that tumor patients with high expression of Fas had a poorer prognosis; in contrast, patients with high expression of Fas treated with CAR-T cells had significantly longer survival times. This evidence concerns the gene FAS and diffuse large B-cell lymphoma.